AGIOS PHARMACEUTICALS, INC.
Company Stats
- Market Cap
- $2.0B
- as of Sep 30, 2026
- Shares Outstanding
- 59.7M
- Free Float
- 87.5%
Income Statement
- Revenue
- $54.0M
- Operating Income
- -$472.1M
- Net Income
- -$412.8M
- EBITDA
- -$466.9M
- Revenue Growth, 3Y
- 56.0%
- FCF Margin, 3Y Avg
- -959.5%
- FCF Margin, Worst Year
- -1107.5%
Cash Flow
- Free Cash Flow
- -$377.3M
- FCF Yield
- -19.0%
- Owner FCF Yield
- -21.7%
Balance Sheet
- Cash & Equivalents
- $89.1M
Returns & Capital
- SBC, 3Y Avg
- $46.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $54.0M | -$377.3M | -698.3% |
| FY2024 | $36.5M | -$391.5M | -1072.7% |
| FY2023 | $26.8M | -$297.1M | -1107.5% |
| FY2022 | $14.2M | -$314.4M | -2207.6% |
| FY2021 | $0 | -$413.1M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 30, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back